Stanford, California 94305

  • Postpartum Hemorrhage

Purpose:

Although prior dose-finding studies have investigated the optimal bolus dose of oxytocin to initiate adequate uterine tone, it is unclear what oxytocin infusion regimen is required to maintain adequate uterine tone after delivery. The study investigators aim to compare two different infusion rates of oxytocin to assess the optimal infusion regimen for reducing blood loss in women undergoing elective Cesarean delivery.


Study summary:

Oxytocin (pitocin) is a drug commonly used in obstetric practice, and the drug effect is to increase the muscular tone of the uterus to reduce uterine bleeding after neonatal delivery. Pregnant patients undergoing elective (scheduled)Cesarean delivery routinely receive oxytocin after delivery of the baby. Post-delivery, oxytocin is commonly administered as an IV bolus and/or infusion. No previous studies have accurately assessed differences in oxytocin infusions after delivery in patients undergoing elective cesarean delivery. Thus the study aim is to investigate which infusion rate can optimally provide adequate maintenance of uterine tone during Cesarean delivery while being associated with minimal or no maternal side-effects.


Criteria:

Inclusion Criteria: - Healthy pregnant patients with uncomplicated pregnancies: - ASA (American Association of Anesthesiologists) class 1 or 2 patients. - Singleton pregnancies. Exclusion Criteria: - ASA class 3 or 4 patients. - Known drug allergy to intravenous oxytocin. - Significant medical or obstetric disease. - Known uterine abnormality. - Known placental abnormality.


NCT ID:

NCT01932060


Primary Contact:

Principal Investigator
Alexander J Butwick, F.R.C.A.
Stanford University

Alexander J Butwick, F.R.C.A.
Phone: (650) 736-8513
Email: ajbut@stanford.edu


Backup Contact:

N/A


Location Contact:

Stanford, California 94305
United States

Alexander J Butwick, F.R.C.A
Phone: 650-736-8513
Email: ajbut@stanford.edu

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: September 18, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.